Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML

EHA Congress 2022

9 - 12 Jun 2022

Published: 13 Jun 2022

Views: 71

Rating:

Save

Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany

Prof Michael Lübbert presents data from the open-label randomised phase III study of the EORTC Leukemia group, GIMEMA, CELG, and GMDS- SG trial during a press conference at the EHA 2022 meeting.

The study compared the efficacy and safety of 10-day decitabine with conventional 3+7 IC as a treatment before HSCT in older (≥60 years) patients with newly diagnosed AML.

Read our news story here

Related Videos

30 minute infusion of isatuximab shows potential in newly diagnosed multiple...

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

ATRA-ATO regimen with idarubicin could become the new standard of care in high...

Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia ( Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany )

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment

Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )

Triplets for newly diagnosed unfit AML patients could be feasible with...

Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...

Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )

More from ecancer

An Error Occurred: Internal Server Error

Oops! An Error Occurred

The server returned a "500 Internal Server Error".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.